Submitting using AfC-submit-wizard |
Theroadislong (talk | contribs) Declining submission: corp - Submission is about a company or organization not yet shown to meet notability guidelines (AFCH) |
||
Line 1: | Line 1: | ||
⚫ | |||
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=DoubleGrazing|declinets=20240326142312|small=yes|ts=20240326141257}} <!-- Do not remove this line! --> |
|||
{{Short description|Nasdaq-listed biopharmaceutical company}} |
{{Short description|Nasdaq-listed biopharmaceutical company}} |
||
{{Draft topics|medicine-and-health}} |
{{Draft topics|medicine-and-health}} |
||
{{AfC topic|org}} |
{{AfC topic|org}} |
||
{{AfC submission|||ts=20240327100205|u=Pomelosol|ns=118}} |
|||
⚫ | |||
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.<ref>{{Cite web |title=Swiss Zentraler Firmenindex (company register) |url=https://www.zefix.ch/en/search/entity/list/firm/1477715}}</ref><ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref> The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.<ref>{{Cite web |title=sec.gov, shareholders' agreement |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821586/000121390021051257/ea147872-8k_helixacq.htm}}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref> |
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.<ref>{{Cite web |title=Swiss Zentraler Firmenindex (company register) |url=https://www.zefix.ch/en/search/entity/list/firm/1477715}}</ref><ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref> The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.<ref>{{Cite web |title=sec.gov, shareholders' agreement |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001821586/000121390021051257/ea147872-8k_helixacq.htm}}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref> |
Revision as of 10:39, 27 March 2024
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.[1][2] The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.[3][4]
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, Sonelokimab is designed to target inflammation sites directly and, due to its smaller size compared to typical monoclonal antibodies, potentially offers better tissue penetration.[5]
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.[6]
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa[7] and psoriatic arthritis.[8]
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.[9][10]
References
- ^ "Swiss Zentraler Firmenindex (company register)".
- ^ "Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095)".
- ^ "sec.gov, shareholders' agreement".
- ^ "sec.gov, prelim. proxy statement".
- ^ Iznardo, H. (12 August 2021). "Dual inhibition of IL-17A and IL-17F in psoriatic disease". Therapeutic Advances in Chronic Disease. 12. doi:10.1177/20406223211037846.
- ^ Papp, K.A. (2021). "IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study". The Lancet. 397 (10284): 1564–1575. doi:10.1016/S0140-6736(21)00440-2.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". 13 November 2023.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". 15 November 2023.
- ^ "MoonLake Immunotherapeutics AG announces closing business".
- ^ "Nasdaq: MoonLake Immunotherapeutics Class A Ordinary Shares".